TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01809132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline, generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc Sulfate, nutritional supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone, corticosteroid
Study: NCT01582542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured.
Study: NCT03312348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared imaging
Description: Infrared image image acquisition of study participants
Study: NCT04016896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIdowed Elders' LIfestyle after Loss (WELL)
Description: Digital monitoring; motivational health coaching; personalized feedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: psychoeducation plus study assessments controlling for time and attention
Study: NCT01958723

Intervention type: OTHER
Intervention: Hospitalists
Description: Introduction of Problem Specific Templates
Study: NCT04466644

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Antibody test (serology) in the blood samples to determine if the subject was previously infected.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
Study: NCT03226418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glasdegib
Description: oral tablet
Study: NCT03457545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aidcube
Description: Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
Study: NCT02357134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive high-flow oxygen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive high-flow air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Therapy
Description: Receive low-flow oxygen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Therapy
Description: Receive low-flow air
Study: NCT04055181

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS in schizophrenia Controls
Description: all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS in schizophrenia patients
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS in major depressive disorders controls
Description: all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS in major depressive disorders patients
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
Study: NCT03305939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style Intervention
Description: The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context.
Study: NCT02163460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain
Description: In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Tension Sutures
Description: Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
Study: NCT04032691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: 0.1 mg by mouth daily at bedtime for one week
Study: NCT02668653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00462995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg once a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
Study: NCT02048670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Belt
Description: Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Belt
Description: Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
Study: NCT00722072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
Study: NCT03583450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative virtual reality headset with mobile app
Description: Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
Study: NCT04621734

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMT BridlePro Device
Description: A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive Tape
Description: Adhesive tape used to secure nasoenteric tube
Study: NCT03177616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Treatment
Description: The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports
Study: NCT03502239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mega Team - video game
Description: Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
Study: NCT01440868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation
Description: Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
Study: NCT01031550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflurane
Description: isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: standard of care
Study: NCT01297764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Description: Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40
Study: NCT04546568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC
Description: FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study: NCT01957995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosomal docetaxel lipid suspension
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosomal docetaxel lipid suspension
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosomal docetaxel lipid suspension
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosomal docetaxel lipid suspension
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00067002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded allogeneic cord blood (CB)
Description: Transplantation of Two Unmanipulated Cord Blood Units.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Unmanipulated and One Expanded Cord Blood Unit
Description: Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
Study: NCT00610545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Study: NCT03858790

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PINS Spinal Cord Stimulator
Description: Subjects will be implanted with PINS spinal cord stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Spinal Cord Stimulator
Description: Subjects will be implanted with PINS spinal cord stimulator
Study: NCT00467779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose
Study: NCT00067002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/Kg by vein on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 by vein on Days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 by vein on Days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg by vein on Day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Total body irradiation (TBI) given on Day -1 at 2 Gy.
Study: NCT03315663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App & DBWS
Description: Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App Alone
Description: Usual care for prediabetes management, Sweetch app alone.
Study: NCT01099176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
Study: NCT04580979

Intervention type: GENETIC
Intervention: Mutation analysis
Description: The investigators will sequence DNA samples from the patients or their families.
Study: NCT00843700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Trauma in Community Settings
Description: Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individual psychotherapy following usual care practice in a community mental health center.
Study: NCT00467779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: In Stage III only: single dose of dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: In Stage III only: single dose of midazolam
Study: NCT06149390

Intervention type: DRUG
Intervention: consolidation with ASCT
Description: high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
Study: NCT03632109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin 360mg IM
Description: 360mg IM of gentamicin
Study: NCT01444014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
Study: NCT00437385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCAs, SSRIs, NARIs, SNRIs, Lithium
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCAs, SSRIs, NARIs, SNRIs, Lithium
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCAs, SSRIs, NARIs, SNRIs, Lithium
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy
Description: The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up.
Study: NCT00153647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-assisted colonoscopy
Description: Cap-assisted colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cap-assisted colonoscopy
Description: Cap-assisted colonoscopy